Coexpression of IL-6 and TNF-α: prognostic significance on breast cancer outcome.

@article{Tripsianis2014CoexpressionOI,
  title={Coexpression of IL-6 and TNF-$\alpha$: prognostic significance on breast cancer outcome.},
  author={Gregory A Tripsianis and Evropi G Papadopoulou and Konstantinos Anagnostopoulos and Sotirios Botaitis and Michael Katotomichelakis and Konstantinos Romanidis and Emmanuel N Kontomanolis and Ioannis K. Tentes and Alexandros H. Kortsaris},
  journal={Neoplasma},
  year={2014},
  volume={61 2},
  pages={
          205-12
        }
}
Presented study was conducted to investigate the prognostic significance of the coexpression of serum interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) in breast cancer, by correlating their presence with clinicopathological characteristics indicative of tumor progression and the overall survival of breast cancer patients. One hundred twelve consecutive patients with primary breast cancer were prospectively included and evaluated. Serum concentrations of IL-6 and TNF-a were measured by… 

Figures and Tables from this paper

Prognostic significance of inflammatory factors expression by stroma from breast carcinomas.

The combination of the expression of IL-1β, IL-6 and IL-10 may serve as promising biomarkers of MICs with prognostic significance, contributing to a better characterization of breast carcinomas microenvironment.

Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer

Increased levels of IL-6 and IL-8 are associated with factors of worse prognosis in ovarian cancer, and additional studies are needed to confirm the role of cytokines as prognostic factors, in the definition of treatment, and in the development of future target therapies.

Pro-Inflammatory and Anti-Inflammatory Salivary Cytokines in Breast Cancer: Relationship with Clinicopathological Characteristics of the Tumor

The aim of the work was to compare the salivary cytokine profile of breast cancer patients with the clinicopathological characteristics of the tumor and the relationship between the level of IL-2, IL-10, and IL-18 in saliva with thelevel of Ki-67 expression has been established.

HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β

A rationale for a breast cancer treatment regime that simultaneously suppresses multiple targets, as these cytokines possess many overlapping functions that increase metastasis and worsen patient survival is provided.

The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches

The known molecular effects of TNF-α signaling in breast cancer cells are corroborated with the results from several preclinical and clinical trials, including T NF-α-related clinical observations, and a pro-tumorigenic role is revealed during breast cancer progression and metastasis.

AVALIAÇÃO DE BIOMARCADORES INFLAMATÓRIOS MOLECULARES EM PACIENTES COM CÂNCER DE MAMA

The data suggests no differences in the levels of MPs and inflammatory cytokines comparing breast cancer patients and healthy women, but breast cancer seems to have a more localized inflammatory response and induces a modulation of the immune system response.

Significance of Interleukin-6 in Papillary Thyroid Carcinoma

IL-6 has an important role in thyroid cancer progression and targeting IL-6 signalling can help in clinical management of thyroid carcinoma patients, according to this study.

The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis

It is suggested that NLR is a good prognostic marker for BC, and patients with a higher NLR have poorer prognoses, and future studies should perform more detailed investigations to decrease heterogeneity and determine the appropriate cut-off values for different races.

Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients.

In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress.
...

References

SHOWING 1-10 OF 43 REFERENCES

Serum Level of Interleukin 6 & Tumor Necrosis Factor in Iraqi Breast Cancer patients

  • Medicine, Biology
  • 2012
The results indicate that serum IL‐6 and TNF – α level may be used in the assessment of breast cancer patients, and suggest that IL‐ 6 produced from breast cancer cells are more resistant to chemotherapeutic agents and yield poor survivals.

Significance of interleukin-6 (IL-6) in breast cancer (review)

The role of IL-6 in in vitro experiments of breast tumor cells, in breast tumor tissues (BTs) and its potential as a prognostic indicator in breast cancer patients is reviewed and data are surprisingly unique showing IL- 6 to be a negative prognosticator in breast tumors patients.

Oestrogen receptor negative breast cancers exhibit high cytokine content

It is found that multiple cytokines were overexpressed in oestrogen receptor negative breast carcinoma, and that the three major cytokines – MCP-1, MIP-1β and IL-8 – were correlated with inflammatory cell component, which could account for the aggressiveness of these tumours.

Potential prognostic and therapeutic roles for cytokines in breast cancer (Review).

The role of cytokines in the immune response against breast cancer and their potential as prognostic indicators and/or use in immune therapy are reviewed.

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

BACKGROUND For optimum management of patients with cancer, accurate assessment of prognosis is essential. The primary determinant of outcome in malignancy is the formation of distant metastases.

Cytokines in breast cancer.

The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.

It is confirmed that serum HER-2 could be used clinically as a useful tumor marker for the diagnosis and the progression of breast cancer and it can be regarded as a predictive biomarker for breast cancer patients with poor prognosis.

Impact of TNF-α and IL-6 Levels on Development of Cachexia in Newly Diagnosed NSCLC Patients

The significant correlation of ESR with TNF-α suggested that ESR could provide valuable clue for considerable weight loss in the follow-up of NSCLC patients, and significant correlations between IL-6, BMI, and T NF- α suggested that these cytokines acted as cofactors in weight loss.

SERUM Ig AND CYTOKINE LEVELS IN WOMEN WITH BREAST CANCER BEFORE AND AFTER MASTECTOMY

The elevation of serum IgG, IgA, C3, C4, IL-6, and TNF-α levels can be considered as an indication for disease status before and after treatment as well as relapses.

IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-Induced STAT3 phosphorylation in human hepatocellular cancer cells

FLLL32 is a novel curcumin analogue, which has been described to suppress the constitutive activation of STAT3 in pancreatic and breast cancer cells in vitro and vivo, and it is demonstrated that FLLL 32 blocked IL-6-induced STAT3 phosphorylation and nuclear translocation in HCC cells.